Published in:
14-04-2023 | Obesity | Original Article
Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity
Published in: International Journal of Diabetes in Developing Countries | Issue 1/2024
Login to get accessAbstract
Background
Factors regarding exenatide-related weight loss have been underrecognized. We aimed to reveal the association between free T4 (fT4) level and exenatide-related weight loss, and change in thyroid function with exenatide treatment in euthyroid adult patients with type 2 diabetes and obesity.
Methods
We included euthyroid adult patients with type 2 diabetes and obesity whom exenatide was added to metformin treatment. We excluded those with contraindication to exenatide or history of thyroid dysfunction. We analyzed baseline demographic, clinical and laboratory features, and the change (difference between the last [6th month] and baseline levels) in body weight, body mass index (BMI), TSH, fT4, fasting blood glucose, HbA1c. We grouped them as Group A: weight loss-absent vs. Group B: weight loss-present (<10%/ ≥10%).
Results
In total (n = 106), TSH-change was -0.077(±1.10), and fT4-change -0.0123(±0.20) (p = 0.229 and p = 0.908, respectively). TSH decreased more in group A than in Group B (p = 0.018). Baseline and the last fT4 levels were higher in group B (p = 0.010 and p = 0.004, respectively). ROC curve analysis indicated that baseline fT4 (cut-off:1.16 ng/dL, AUC:0.708, p = 0.010) was associated with weight loss. The ratio of patients having higher baseline fT4 (≥1.16) was higher in group B (p = 0.016). Baseline BMI (≥40 kg/m2) and fT4 (≥1.16 ng/dL) levels were positive predictors for weight loss (p = 0.024 and p = 0.013, respectively). Decrease in BMI was negatively correlated with baseline BMI (p = 0.002).
Conclusion
Exenatide provides more weight loss in the patients with higher baseline BMI or fT4. Thyroid function remains unchanged during treatment.